BioLineRx Finalizes $3.75M Offering with Warrant Repricing and Lock-Ups
BLRX sits 27% above its 52-week low of $2.15 on elevated volume (9.5× avg).
Summary
BioLineRx finalized its $3.75M offering at $2.78/ADS, adding warrant repricing, tail fees, and lock-up restrictions. The capital is essential given the company's going-concern warning and limited cash.
Key Events · Financing and Capital Events · BLRX
-
Offering Finalized at $2.78/ADS
480,696 ADSs plus pre-funded warrants for 868,225 ADSs sold at $2.78, raising $3.75M gross ($3.3M net).
-
Warrant Repricing and Extension
Investor's existing warrants for 277,273 ADSs repriced to $2.78 and extended to August 31, 2031.
-
Tail Fee to Prior Placement Agent
H.C. Wainwright receives $262,500 cash plus warrants for 67,446 ADSs at $3.475 exercise price.
-
Lock-Up Restrictions
60-day ban on new issuances; 120-day ban on variable-rate transactions, with ATM carve-out after 60 days.
Analysis · BLRX · Life Sciences
This prospectus supplement finalizes the $3.75 million registered direct offering priced on August 28, adding material new terms: the investor's existing warrants are repriced to $2.78 and extended to 2031, a prior placement agent receives a $262,500 tail fee plus warrants, and the company agrees to 60-day issuance and 120-day variable-rate-transaction lock-ups. The deal comes as BioLineRx disclosed going-concern uncertainty with only $13.1 million in cash, making this capital raise critical for near-term runway despite the dilution.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.1% of the 2014 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLRX was trading at $2.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.1M. The 52-week trading range was $2.15 to $4.56. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.